Colossal Biosciences, a de-extinction startup known for its efforts to resurrect extinct species like the dire wolf, is reportedly in discussions to raise new capital at a valuation between $20 billion and $30 billion.This follows its previous $10.2 billion valuation and marks significant growth over 16 months.The company has already begun generating revenue through contracts with the U.S.government and the UAE, which invested $60 million in 2025.

Colossal has spun off three startups, including Breaking (plastic breakdown), Form Bio (computational biology), and Astromech (AI-driven predictive modeling).CEO Ben Lamm highlighted plans to commercialize artificial animal womb technology for human fertility applications, expected by 2027.The fundraising comes amid a boom in deep-tech sectors like longevity tech and alternative energy.

While the company has not commented on the report, its advancements in genetic engineering and conservation tech position it as a key player in biotech innovation.